Impact of variations in triage cytology interpretation on human papillomavirus–based cervical screening and implications for screening algorithms

European Journal of Cancer

Volumn 68, Issue , 2016, Pages 148-155

  Ronco, Guglielmo ^t   Zappa, Marco ^u   Franceschi, Silvia ^v   Tunesi, Sara ^t,w   Caprioglio, Adele ^t   Confortini, Massimo ^u   Del Mistro, Annarosa ^x   Carozzi, Francesca ^u   Segnan, Nereo ^t   Zorzi, Manuel ^y   Giorgi Rossi, Paolo ^k,z   Gillio Tos, A ^a   Giubilato, P ^a   Pasquale, L ^b   Luciano, G ^b   Polla, E ^c   Dalla Palma, P ^c   Fedato, C ^d   Zago, F ^e   Pupo, A ^f   Simoncello, I ^g   Penon, M G ^h   Gallo, L ⁱ   Del Sole, A ^j   Paterlini, L ^k   Campari, C ^k   Iossa, A ^l   Barca, A ^m   Tufi, M C ⁿ   Bellardini, P ^o   Fortunato, C ^p   Minna, M ^q   Macerola, A ^r   Caraceni, D ^s   more..

^a CPO Piemonte   (Italy)

^b ASL Vallecamonica Sebino   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d Regione Veneto   (Italy)

^e ULSS 12   (Italy)

^f UO di Ginecologia e Ostetricia   (Italy)

^g ULSS 16   (Italy)

^h General Surgery Division   (Italy)

ⁱ ULSS 18   (Italy)

^j ULSS 19 Adria   (Italy)

^k PATHOLOGY UNIT   (Italy)

^l ISPO   (Italy)

^m Regione Lazio   (Italy)

ⁿ ASL Roma G   (Italy)

^o ASL Latina   (Italy)

^p ASL Teramo   (Italy)

^q ASL Pescara   (Italy)

^r ASL Av Sulmona L'Aquila   (Italy)

^s ASL Lanciano Vasto Chieti   (Italy)

^t CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^u Institute for Study and Cancer Prevention (ISPO)   (Italy)

^v INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^w UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^x VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^y Registro Tumori Veneto   (Italy)

^z S MARIA NUOVA HOSPITAL   (Italy)

more..

Author keywords

Cervical cancer; Cytology; Human papillomavirus; Screening; Triage

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RAPID TEST; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; ALGORITHM; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY CANCER DIAGNOSIS; EMERGENCY HEALTH SERVICE; ITALY; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX DYSPLASIA; VAGINA SMEAR; VIROLOGY;

ADULT; ALGORITHMS; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; ITALY; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84991699745     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.09.008     Document Type: Article

References (32)

1. [1] Arbyn, M., Ronco, G., Anttila, A., Meijer, C.J.L.M., Poljak, M., Ogilvie, G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:Suppl. 5 (2012 Nov 20), F88–F99.
2. [2] Ronco, G., Dillner, J., Elfström, K.M., Tunesi, S., Snijders, P.J.F., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:9916 (2014), 524–532.
3. [3] Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:16 (2007 Oct 18), 1589–1597.
4. [4] Kitchener, H.C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10 (2009), 672–682.
5. [5] Rijkaart, D.C., Berkhof, J., Rozendaal, L., van Kemenade, F.J., Bulkmans, N.W.J., Heideman, D.A.M., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13 (2012), 78–88.
6. [6] Massad, L.S., Einstein, M.H., Huh, W.K., Katki, H.A., Kinney, W.K., Schiffman, M., et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obst Gynecol 121 (2013), 829–846.
7. [7] Bergeron, C., Giorgi-Rossi, P., Cas, F., Schiboni, M.L., Ghiringhello, B., Dalla Palma, P., et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst, 107(12), 2015, 10.1093/jnci/dju423 dju423.
8. [8] Leinonen, M., Nieminen, P., Kotaniemi-Talonen, L., Malila, N., Tarkkanen, J., Laurila, P., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 101 (2009), 1612–1623.
9. [9] Castle, P.E., Stoler, M.H., Wright, T.C., Sharma, A., Wright, T.L., Behrens, C.M., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12 (2011), 880–890.
10. [10] Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., Gillio-Tos, A., De Marco, L., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 9 (2008), 937–945.
11. [11] Carozzi, F., Gillio-Tos, A., Confortini, M., Del Mistro, A., Sani, C., De Marco, L., et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 14 (2013), 168–176.
12. [12] Petry, K.U., Schmidt, D., Scherbring, S., Luyten, A., Reinecke-Lüthge, A., Bergeron, C., et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 121 (2011), 505–509.
13. [13] Wentzensen, N., Fetterman, B., Castle, P.E., Schiffman, M., Wood, S.N., Stiemerling, E., et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst, 107(12), 2015 Sept 15, 10.1093/jnci/djv257 pii: djv257. Print 2015 Dec.
14. [14] Uijterwaal, M.H., Polman, N.J., Witte, B.I., van Kemenade, F.J., Rijkaart, D., Berkhof, J., et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer 136:10 (2015 May 15), 2361–2368, 10.1002/ijc.29290 [Epub 2014 Nov 6].
15. [15] De Strooper, L.M.A., Meijer, C.J.L.M., Berkhof, J., Hesselink, A.T., Snijders, P.J.F., Steenbergen, R.D.M., et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila) 7 (2014 Dec), 1251–1257, 10.1158/1940-6207.CAPR-14-0237 [Epub 2014 Oct 3].
16. [16] De Strooper, L.M.A., Hesselink, A.T., Berkhof, J., Meijer, C.J.L.M., Snijders, P.J.F., Steenbergen, R.D.M., et al. Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev 23:9 (2014 Sep), 1933–1937, 10.1158/1055-9965.EPI-14-0347 [Epub 2014 Jun 24].
17. [17] Verhoef, V.M.J., Bosgraaf, R.P., van Kemenade, F.J., Rozendaal, L., Heideman, D.A.M., Hesselink, A.T., et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 15:3 (2014 Mar), 315–322, 10.1016/S1470-2045(14)70019-1 [Epub 2014 Feb 13].
18. [18] Mirabello, L., Sun, C., Ghosh, A., Rodriguez, A.C., Schiffman, M., Wentzensen, N., et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 104:7 (2012 Apr 4), 556–565, 10.1093/jnci/djs135 [Epub 2012 Mar 23].
19. [19] Wentzensen, N., Sun, C., Ghosh, A., Kinney, W., Mirabello, L., Wacholder, S., et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 104:22 (2012 Nov 21), 1738–1749, 10.1093/jnci/djs425 [Epub 2012 Oct 23].
20. [20] Vasiljević, N., Scibior-Bentkowska, D., Brentnall, A., Cuzick, J., Lorincz, A., A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol 59:3 (2014 Mar), 161–166, 10.1016/j.jcv.2013.12.014 [Epub 2014 Jan 8].
21. [21] Valdez, M., Jeronimo, J., Bansil, P., Qiao, Y.-L., Zhao, F.-H., Chen, W., et al. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural China. Int J Cancer 138 (2016 Mar 15), 1453–1461, 10.1002/ijc.29877 [Epub ahead of print].
22. [22] Wentzensen, N., Schiffman, M., Palmer, T., Arbyn, M., Triage of HPV positive women in cervical cancer screening. J Clin Virol 76:Suppl. 1 (2016), S49–S55.
23. [23] Ronco, G., Giorgi Rossi, P., Giubilato, P., Del Mistro, A., Zappa, M., Carozzi, F., et al. A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiol Prev 39:3 Suppl. 1 (2015 May–Jun), 77–83.
24. [24] Ronco, G., Iossa, A., Naldoni, C., Pilutti, S., Anghinoni, E., Zappa, M., et al. A first survey of organized cervical cancer screening programs in Italy. Tumori 84 (1998), 624–630.
25. [25] Ronco, G., Giubilato, P., Carozzi, F., Maia, G., Giorgi Rossi, P., Zappa, M., et al. Extension of organized cervical cancer screening programmes in Italy and their process indicators, 2011–2012 activity. Epidemiol Prev 39:3 Suppl. 1 (2015 May–Jun), 61–76.
26. [26] Ronco, G., Biggeri, A., Confortini, M., Naldoni, C., Segnan, N., Sideri, M., et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemio Prev 36:3–4 Suppl. 1 (2012), 1–72 [Italian].
27. [27] Giorgi-Rossi, P., Franceschi, S., Ronco, G., HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer 130:6 (2012 Mar 2105), 1387–1394.
28. [28] Liang, K.Y., Zeger, S.L., Longitudinal data analysis using generalized linear models. Biometrika 73 (1986), 13–22.
29. [29] Rijkaart, D.C., Berkhof, J., van Kemenade, F.J., Coupe, V.M.H., Hesselink, A.T., Rozendaal, L., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 130 (2012), 602–610.
30. [30] Richardson, H., Kelsall, G., Tellier, P., Voyer, H., Abrahamowicz, M., Ferenczy, A., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12:6 (2003 Jun), 485–490.
31. [31] Veldhuijzen, N.J., Berkhof, J., Gillio-Tos, A., De Marco, L., Carozzi, F., Del Mistro, A., et al. The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomarkers Prev 24 (2015), 111–118.
32. [32] Ronco, G., van Ballegooijen, M., Becker, N., Chil, A., Fender, M., Giubilato, P., et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 45 (2009), 2659–2670.